VEVesela Encheva

Vesela Encheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vesela Encheva has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phenotypic proteomic profiling identifies a landscape of targets for circadian clock–modulating compounds

    by Sandipan Ray, Radoslaw Lach, Kate J Heesom, Utham K Valekunja, Vesela Encheva, Ambrosius P Snijders, Akhilesh B Reddy

    Determining the exact targets and mechanisms of action of drug molecules that modulate circadian rhythms is critical to develop novel compounds to treat clock-related disorders. Here, we have used phenotypic proteomic profiling (PPP) to systematically determine molecular targets of four circadian period–lengthening compounds in human cells. We demonstrate that the compounds cause similar changes in phosphorylation and activity of several proteins and kinases involved in vital pathways, including MAPK, NGF, B-cell receptor, AMP-activated protein kinases (AMPKs), and mTOR signaling. Kinome profiling further indicated inhibition of CKId, ERK1/2, CDK2/7, TNIK, and MST4 kinases as a common mechanism of action for these clock-modulating compounds. Pharmacological or genetic inhibition of several convergent kinases lengthened circadian period, establishing them as novel circadian targets. Finally, thermal stability profiling revealed binding of the compounds to clock regulatory kinases, signaling molecules, and ubiquitination proteins. Thus, phenotypic proteomic profiling defines novel clock effectors that could directly inform precise therapeutic targeting of the circadian system in humans.


  • Open Access

    Protein ubiquitylation is essential for the schizont to merozoite transition in Plasmodium falciparum blood-stage development

    by Yang Wu, Vesela Encheva, Judith L. Green, Edwin Lasonder, Adchara Prommaban, Simone Kunzelmann, Evangelos Christodoulou, Munira Grainger, Ngoc Truongvan, Sebastian Bothe, et al.

    Ubiquitylation is a common post translational modification of eukaryotic proteins and in the human malaria parasite, Plasmodium falciparum (Pf) overall ubiquitylation increases in the transition from intracellular schizont to extracellular merozoite stages in the asexual blood stage cycle. Here, we identify specific ubiquitylation sites of protein substrates in three intracellular parasite stages and extracellular merozoites; a total of 1464 sites in 546 proteins were identified (data available via ProteomeXchange with identifier PXD014998). 469 ubiquitylated proteins were identified in merozoites compared with only 160 in the preceding intracellular schizont stage, indicating a large increase in protein ubiquitylation associated with merozoite maturation. Following merozoite invasion of erythrocytes, few ubiquitylated proteins were detected in the first intracellular ring stage but as parasites matured through trophozoite to schizont stages the extent of ubiquitylation increased. We identified commonly used ubiquitylation motifs and groups of ubiquitylated proteins in specific areas of cellular function, for example merozoite pellicle proteins involved in erythrocyte invasion, exported proteins, and histones. To investigate the importance of ubiquitylation we screened ubiquitin pathway inhibitors in a parasite growth assay and identified the ubiquitin activating enzyme (UBA1 or E1) inhibitor MLN7243 (TAK-243) to be particularly effective. This small molecule was shown to be a potent inhibitor of recombinant PfUBA1, and a structural homology model of MLN7243 bound to the parasite enzyme highlights avenues for the development of P. falciparum specific inhibitors. We created a genetically modified parasite with a rapamycin-inducible functional deletion of uba1; addition of either MLN7243 or rapamycin to the recombinant parasite line resulted in the same phenotype, with parasite development blocked at the late schizont stage. These results indicate that the intracellular target of MLN7243 is UBA1, and this activity is essential for the final differentiation of schizonts to merozoites. The ubiquitylation of many merozoite proteins and their disappearance in ring stages are consistent with the idea that ubiquitylation leads to their destruction via the proteasome once their function is complete following invasion, which would allow amino acid recycling in the period prior to the parasite’s elaboration of a new food vacuole.


  • Open Access

    Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation

    by Jamie A Macpherson, Alina Theisen, Laura Masino, Louise Fets, Paul C Driscoll, Vesela Encheva, Ambrosius P Snijders, Stephen R Martin, Jens Kleinjung, Perdita E Barran, et al.

    Several enzymes can simultaneously interact with multiple intracellular metabolites, however, how the allosteric effects of distinct ligands are integrated to coordinately control enzymatic activity remains poorly understood. We addressed this question using, as a model system, the glycolytic enzyme pyruvate kinase M2 (PKM2). We show that the PKM2 activator fructose 1,6-bisphosphate (FBP) alone promotes tetramerisation and increases PKM2 activity, but addition of the inhibitor L-phenylalanine (Phe) prevents maximal activation of FBP-bound PKM2 tetramers. We developed a method, AlloHubMat, that uses eigenvalue decomposition of mutual information derived from molecular dynamics trajectories to identify residues that mediate FBP-induced allostery. Experimental mutagenesis of these residues identified PKM2 variants in which activation by FBP remains intact but cannot be attenuated by Phe. Our findings reveal residues involved in FBP-induced allostery that enable the integration of allosteric input from Phe and provide a paradigm for the coordinate regulation of enzymatic activity by simultaneous allosteric inputs.


  • Open Access

    Analysis of RNA polymerase II ubiquitylation and proteasomal degradation

    by Ana Tufegdzic Vidakovic, Michelle Harreman, A. Barbara Dirac-Svejstrup, Stefan Boeing, Anindya Roy, Vesela Encheva, Michelle Neumann, Marcus Wilson, Ambrosius P. Snijders, Jesper Q. Svejstrup


  • Open Access

    LUBAC determines chemotherapy resistance in squamous cell lung cancer

    by E. Josue Ruiz, Markus E. Diefenbacher, Jessica K. Nelson, Rocio Sancho, Fabio Pucci, Atanu Chakraborty, Paula Moreno, Alessandro Annibaldi, Gianmaria Liccardi, Vesela Encheva, et al.

    Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC) are the most common lung cancer subtypes. Molecular targeted treatments have improved LADC patient survival but are largely ineffective in LSCC. The tumor suppressor FBW7 is commonly mutated or down-regulated in human LSCC, and oncogenic KRasG12D activation combined with Fbxw7 inactivation in mice (KF model) caused both LSCC and LADC. Lineage-tracing experiments showed that CC10+, but not basal, cells are the cells of origin of LSCC in KF mice. KF LSCC tumors recapitulated human LSCC resistance to cisplatin-based chemotherapy, and we identified LUBAC-mediated NF-κB signaling as a determinant of chemotherapy resistance in human and mouse. Inhibition of NF-κB activation using TAK1 or LUBAC inhibitors resensitized LSCC tumors to cisplatin, suggesting a future avenue for LSCC patient treatment.


  • Open Access

    SETDB1 Links the Meiotic DNA Damage Response to Sex Chromosome Silencing in Mice

    by Takayuki Hirota, Paul Blakeley, Mahesh N. Sangrithi, Shantha K. Mahadevaiah, Vesela Encheva, Ambrosius P. Snijders, Elias ElInati, Obah A. Ojarikre, Dirk G. de Rooij, Kathy K. Niakan, et al.


  • Open Access

    Murine Gbp1 and Gbp2 are ubiquitinated independent of Toxoplasma gondii infection

    by Vesela Encheva, Clémence Foltz, Ambrosius P. Snijders, Eva-Maria Frickel

    The intracellular parasite Toxoplasma gondii can invade any nucleated cell residing inside a parasitophorous vacuole (PV). Upon infection, the cytokine interferon gamma (IFNγ) is produced and elicits host defence mechanisms able to recognise the PV and destroy the parasite. Hereby, Guanylate binding proteins, ubiquitin and the E3 ubiquitin ligases Tripartite Motif Containing 21 (TRIM21) and TNF receptor associated factor 6 are targeted to the murine PV leading to its destruction. This study is the side product of research aiming to identify ubiquitinated substrates in a TRIM21-dependent fashion in murine cells infected with Toxoplasma. We infected IFNγ-stimulated murine embryonic fibroblasts (MEFs) from either C57BL/6×129 wild-type (WT) mice or C57BL/6 TRIM21−/− mice with Toxoplasma. Using mass spectrometry, we analysed proteins in both cell backgrounds presenting with the di-glycine remnant of ubiquitination. In addition, we compared peptide levels between WT and TRIM21−/− cells. In line with earlier reports, Gbp1 was expressed to higher levels in the C57BL/6×129 WT MEFs compared to the C57BL/6-only background TRIM21−/− MEFs. Protein expression differences in these different murine backgrounds thus precluded identification of TRIM21-dependent ubiquitinated substrates. Nevertheless, we identified and confirmed Gbp1 and Gbp2 as being ubiquitinated in a Toxoplasma-infection independent manner.


  • Open Access

    USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination

    by Laura Novellasdemunt, Valentina Foglizzo, Laura Cuadrado, Pedro Antas, Anna Kucharska, Vesela Encheva, Ambrosius P. Snijders, Vivian S.W. Li


  • Open Access

    Centriolar Satellites Control GABARAP Ubiquitination and GABARAP-Mediated Autophagy

    by Justin Joachim, Minoo Razi, Delphine Judith, Martina Wirth, Emily Calamita, Vesela Encheva, Brian D. Dynlacht, Ambrosius P. Snijders, Nicola O’reilly, Harold B.J. Jefferies, et al.


  • Open Access

    Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway

    by Valentina Rapisarda, Michela Borghesan, Veronica Miguela, Vesela Encheva, Ambrosius P. Snijders, Amaia Lujambio, Ana O’lOghlen